Abstract
Cancer patients are often treated with biological response modifiers to enhance immunological functions. However, little is known about the actual mechanism of action of many of these substances. Therefore, we were interested in the effect of i.p. treatment with porcine low-molecular-weight spleen peptides, which are used during supportive cancer therapy, on lymphoid cell populations and function in mice. After treatment with 0.5 μg peptides/kg body weight for 14 consecutive days, lymphokine secretion and the generation of cytotoxic T-cells were significantly enhanced as compared with controls. However, there was no effect on the number of cells or the percentage of cells expressing functional surface markers in secondary lymphoid organs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Audhya T, Schlesinger DH, Goldstein G (1981) Complete amino acid sequence of bovine thymopoietins I, II and III: closely homologous polypeptides. Biochemistry 20:6195–6200
Audhya T, Scheid MP, Goldstein G (1984) Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc Natl Acad Sci USA 81:2847–2849
Baier JE, Neumann HA, Gallati H, Ricken D (1991) Improvement of impaired mitogen-induced interferon-gamma release of peripheral blood mononuclear cells derived from tumor patients by Polyerga. Onkologie 14 [Suppl 2]:7
Baier JE, Neumann HA, Taufighi-Chirazi T, Gallati H, Ricken D (1994) Thymopentin factor AF2 and Polyerga improve impaired mitogen-induced interferon-gamma release of peripheral blood mononuclear cells derived from tumor patients. Tumordiagn Ther 15: 21–26
Barasoain I, Rejas MT, Portolés MP, Ojeda G, Rojo JM (1987) Isoprinosine restores in vitro T-lymphocyte functions of cyclophosphamide immunosuppressed mice. Int J Immunopharmacol 9:489–496
Berressem P (1991) Adjuvant therapy in breast cancer. Gynäkologie 7:37–44
Bottomly K, Luqman M, Greenbaum L, Carding S, West J, Pasqualini T, Murphy DB (1989) A monoclonal antibody to murine CD45R distinguished CD3 T-cell populations that produce different cytokines. Eur J Immunol 19:617–623
Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D (1980) Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 152:1036–1047
Dialynas DP, Wilde DB, Marrack P, Pierres A, Wall K, Harran W, Otten G, Liken M, Pierres M, Kappler J, Fitch F (1983) Characterisation of the murine antigenic determinant designated L3T4a by functional T-cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 74:29–56
Diezel W, Eckert R, Volk HD, Goan SR, Forner K, Baehr R, Sönnichsen N, Oehme N (1987) Splenopentin—biological activities and therapeutic aspects. Z Klin Med 42:15–18
Diezel W, Volk HD, Daniel V, Gruner S, Sönnichsen N (1989) Immunostimulants—immunotherapy. Arch Geschwulstforsch 59:45–51
Doherty PC, Allen W, Eichelberger M (1992) Roles of αβ and σ T-cell subsets in viral immunity. Annu Rev Immunol 10:123–151
Engleman EG, Benike CJ, Grumet FC, Evans RL (1981) Activation of human T-lymphocyte subsets: helper and suppressor/cytotoxic cells recognise and respond to distinct histocompatibility antigens. J Immunol 127:2124–2129
Gillis S, Ferm MM, Ou W, Smith KA (1978) T-cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027–2032
Jayatilake RS, Balawardena J, Skiba G, Hartleb M (1992) Spleen peptides enhance body weight, subjective well-being and appetite in cancer patients. J Cancer Res Clin Oncol 118:R 36
Jones B, Janeway CA (1981) Functional activities of antibodies against brain-associated T-cell antigens. Eur J Immunol 11:584–592
Landgraf G (1992) Cancer therapy in daily practice. Allg Med 23:764–767
Ledbetter JA, Herzenberg LA (1979) Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 47:63–90
Leo O, Foo M, Sachs H, Samelson EL, Bluestone A (1987) Identification of a monoclonal antibody specific for murine T3. Proc Natl Acad Sci USA 84:1374–1378
Moller T (ed) (1986) IL-2: Receptors and genes. Immunol Rev 92
Mossmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Nabholz M, McDonald HR (1983) Cytolytic T-lymphocytes. Annu Rev Immunol 1:273–306
Pestka S, Langer JA (1987) Interferons and their action. Annu Rev Biochem 56:727–777
Portolés P, Rojo JM, Golby A, Bonneville M, Gromkowski S, Greenbaum L, Janeway A, Murphy DB (1989) Monoclonal antibodies to murine CD3e define distinct epitopes, one of which may interact with CD3 during T-cell activation. J Immunol 142:4169–4175
Sattar N, Mihelic M, Shekhani MS, Hartleb M, Folkers K, Voelter W (1991) A modified E-rosette assay as a semiempirical tool in search of new T-lymphocyte stimulants. Immunol Lett 27:221–224
Springer T, Galfré G, Secher DS, Milstein C (1979) Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 9:301–306
Warner NL, Daley MJ, Richey J, Spellman C (1979) Flow cytometry analysis of murine B cell lymphoma differentiation. Immunol Rev 48:197–243
Zarkovic N, Ilic Z, Hrzenjak M, Saric T, Bogdanovic M, Jurin M (1990) Comparison of the effect of porcine splenic peptides on the immune reactivity of normal and tumor-bearing mice. Period Biol 92 [Suppl 3]:W9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Ojeda, G., Diez-Orejas, R., Portolés, P. et al. Polyerga, a biological response modifier enhancing T-lymphocyte-dependent responses. Res. Exp. Med. 194, 261–267 (1994). https://doi.org/10.1007/BF02576387
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02576387